1 | partially | 3,524 |
2 | partly | 1,989 |
3 | temporarily | 345 |
4 | virologically | 109 |
5 | sympathetically | 26 |
6 | neutrally | 14 |
7 | hepatically | 12 |
8 | segmentally | 11 |
9 | faintly | 10 |
10 | vagally | 10 |
11 | forcibly | 8 |
12 | autonomically | 7 |
13 | anti-egfr-igg3 | 5 |
14 | cholinergically | 5 |
15 | interval/patient | 5 |
16 | serotonergically | 5 |
17 | subconsciously | 5 |
18 | tidally | 5 |
19 | artifactually | 4 |
20 | gestationally | 4 |
21 | lack-of-fit | 4 |
22 | non-ige | 4 |
23 | phosphanyl | 4 |
24 | pre-blood | 4 |
25 | 35dry | 3 |
26 | isocapnia | 3 |
27 | isoenergetically | 3 |
28 | metal-on-highly | 3 |
29 | microfat | 3 |
30 | ns8593 | 3 |
31 | p-tscl | 3 |
32 | provocatively | 3 |
33 | steroidsulfatase | 3 |
34 | 2-amino-5-arylazo-6-aryl | 2 |
35 | 3,063 | 2 |
36 | 58802 | 2 |
37 | alu-alu | 2 |
38 | anti-mir-302a | 2 |
39 | aps-treatment | 2 |
40 | are5 | 2 |
41 | cognitive-behaviorally | 2 |
42 | conically | 2 |
43 | cyp21a1 | 2 |
44 | dad-induced | 2 |
45 | extracellular-signal | 2 |
46 | indications/settings | 2 |
47 | n-ethyl-2-pyrrolidinone | 2 |
48 | parasympathetically | 2 |
49 | partialy | 2 |
50 | phospho-signaling | 2 |
51 | polyclonally | 2 |
52 | prefrontally | 2 |
53 | selene | 2 |
54 | stattic | 2 |
55 | t-roundness | 2 |
56 | thiazolidin-4-ones | 2 |
57 | tim-3-expression | 2 |
58 | unfeasibility | 2 |
59 | wbc-derived | 2 |
60 | work/daycare | 2 |
61 | 'focally | 1 |
62 | 'pathophysiologically | 1 |
63 | -acetophenones | 1 |
64 | -asset-building | 1 |
65 | -c19 | 1 |
66 | -olefinic | 1 |
67 | -sparteine | 1 |
68 | 0.5-1.5°c | 1 |
69 | 1-methyl-5-nitroimidazole-2-aldehyde | 1 |
70 | 109513 | 1 |
71 | 10‰ | 1 |
72 | 14,226 | 1 |
73 | 2,2-unsymmetrically | 1 |
74 | 3',5'-adenosine | 1 |
75 | 3-aminodiarylisoxazoles | 1 |
76 | 3-arylidene | 1 |
77 | 3-methoxy- | 1 |
78 | 3.8±0.3 | 1 |
79 | 329.467 | 1 |
80 | 4-hydroxycarbazoles | 1 |
81 | 46,81 | 1 |
82 | 6-phenyl | 1 |
83 | 6569dalys/year | 1 |
84 | 6β-cinnamoylmorphinamine | 1 |
85 | 7-phosphadibenzonorbornadiene | 1 |
86 | 782,850 | 1 |
87 | aaph- | 1 |
88 | activity/seasonality | 1 |
89 | adrenergically | 1 |
90 | alkyl-3-oxobutanoates | 1 |
91 | amphetaime | 1 |
92 | arctherapy | 1 |
93 | aspirin/dipyridamole | 1 |
94 | b6.ahr+/+ | 1 |
95 | bacteriaceae | 1 |
96 | baroreflexly | 1 |
97 | bcc-ti-phase | 1 |
98 | beta2-adrenergically | 1 |
99 | binaphthoxide | 1 |
100 | c-met-activation | 1 |
101 | cationization | 1 |
102 | ceramic-on-highly | 1 |
103 | charge-to-alanine | 1 |
104 | collicularly | 1 |
105 | compounds/metabolites | 1 |
106 | concems | 1 |
107 | craniocentricity | 1 |
108 | cyp1b2 | 1 |
109 | cys269 | 1 |
110 | debrominated | 1 |
111 | described-the | 1 |
112 | determined.ashmi | 1 |
113 | dicubane | 1 |
114 | disclosure/discrimination | 1 |
115 | drift-criterion | 1 |
116 | duration-may | 1 |
117 | extracellular-signaling | 1 |
118 | flufenamate | 1 |
119 | from.50 | 1 |
120 | fxr/fxr-agonist | 1 |
121 | gastronomically | 1 |
122 | hemicidrin | 1 |
123 | heterozygots | 1 |
124 | hplc-purified | 1 |
125 | hypocritically | 1 |
126 | improves/slightly | 1 |
127 | inotropically | 1 |
128 | involved.patients | 1 |
129 | iridodials | 1 |
130 | lioplast | 1 |
131 | lps-applications | 1 |
132 | lrp2 | 1 |
133 | mabtrem-1 | 1 |
134 | marginal-if | 1 |
135 | meta-chloro | 1 |
136 | mono-phosphinoyl/thiophosphinoyl | 1 |
137 | monophenoxy | 1 |
138 | n-oxide-fleroxacin | 1 |
139 | nanotio2 | 1 |
140 | non-axisymmetric | 1 |
141 | non-clathrin | 1 |
142 | non-immunologically | 1 |
143 | non-nhi | 1 |
144 | non-sod | 1 |
145 | nonmasking | 1 |
146 | nonprofessionally | 1 |
147 | p-fluorobenzyl | 1 |
148 | pap1 | 1 |
149 | partly-be | 1 |
150 | partly/fully | 1 |
151 | performance-bias | 1 |
152 | pre-hospital-initiated | 1 |
153 | prohibitted | 1 |
154 | prosthodontically | 1 |
155 | puerperally | 1 |
156 | pyridazin-3-ones | 1 |
157 | rauisuchian | 1 |
158 | reboots | 1 |
159 | reprised | 1 |
160 | rgkitla | 1 |
161 | ru-alkylidene | 1 |
162 | sacm1l | 1 |
163 | self-trapping | 1 |
164 | serum/glucocorticoid | 1 |
165 | situation-based | 1 |
166 | sq29548 | 1 |
167 | sub-aquatic | 1 |
168 | sufonyl | 1 |
169 | sugar/sugar | 1 |
170 | tandem-dimer | 1 |
171 | tat-59 | 1 |
172 | thermo-optically | 1 |
173 | tim-/- | 1 |
174 | tobramycin-impregnated | 1 |
175 | toxicopathological-associated | 1 |
176 | trp67 | 1 |
177 | type-could | 1 |
178 | v-1606 | 1 |
179 | val158-were | 1 |
180 | valence-dependently | 1 |
181 | venostasis | 1 |
182 | wall-power | 1 |
183 | well-tolerated.for | 1 |
184 | wilfordine | 1 |
185 | ±1.5-fold | 1 |
186 | ß-1,6-gal3 | 1 |
187 | α-nf | 1 |
188 | β-dialkyl | 1 |
189 | β1,6 | 1 |
190 | β2-β3 | 1 |
1 | 'focally | 1 |
2 | 'pathophysiologically | 1 |
3 | -acetophenones | 1 |
4 | -asset-building | 1 |
5 | -c19 | 1 |
6 | -olefinic | 1 |
7 | -sparteine | 1 |
8 | 0.5-1.5°c | 1 |
9 | 1-methyl-5-nitroimidazole-2-aldehyde | 1 |
10 | 109513 | 1 |
11 | 10‰ | 1 |
12 | 14,226 | 1 |
13 | 2,2-unsymmetrically | 1 |
14 | 2-amino-5-arylazo-6-aryl | 2 |
15 | 3',5'-adenosine | 1 |
16 | 3,063 | 2 |
17 | 3-aminodiarylisoxazoles | 1 |
18 | 3-arylidene | 1 |
19 | 3-methoxy- | 1 |
20 | 3.8±0.3 | 1 |
21 | 329.467 | 1 |
22 | 35dry | 3 |
23 | 4-hydroxycarbazoles | 1 |
24 | 46,81 | 1 |
25 | 58802 | 2 |
26 | 6-phenyl | 1 |
27 | 6569dalys/year | 1 |
28 | 6β-cinnamoylmorphinamine | 1 |
29 | 7-phosphadibenzonorbornadiene | 1 |
30 | 782,850 | 1 |
31 | aaph- | 1 |
32 | activity/seasonality | 1 |
33 | adrenergically | 1 |
34 | alkyl-3-oxobutanoates | 1 |
35 | alu-alu | 2 |
36 | amphetaime | 1 |
37 | anti-egfr-igg3 | 5 |
38 | anti-mir-302a | 2 |
39 | aps-treatment | 2 |
40 | arctherapy | 1 |
41 | are5 | 2 |
42 | artifactually | 4 |
43 | aspirin/dipyridamole | 1 |
44 | autonomically | 7 |
45 | b6.ahr+/+ | 1 |
46 | bacteriaceae | 1 |
47 | baroreflexly | 1 |
48 | bcc-ti-phase | 1 |
49 | beta2-adrenergically | 1 |
50 | binaphthoxide | 1 |
51 | c-met-activation | 1 |
52 | cationization | 1 |
53 | ceramic-on-highly | 1 |
54 | charge-to-alanine | 1 |
55 | cholinergically | 5 |
56 | cognitive-behaviorally | 2 |
57 | collicularly | 1 |
58 | compounds/metabolites | 1 |
59 | concems | 1 |
60 | conically | 2 |
61 | craniocentricity | 1 |
62 | cyp1b2 | 1 |
63 | cyp21a1 | 2 |
64 | cys269 | 1 |
65 | dad-induced | 2 |
66 | debrominated | 1 |
67 | described-the | 1 |
68 | determined.ashmi | 1 |
69 | dicubane | 1 |
70 | disclosure/discrimination | 1 |
71 | drift-criterion | 1 |
72 | duration-may | 1 |
73 | extracellular-signal | 2 |
74 | extracellular-signaling | 1 |
75 | faintly | 10 |
76 | flufenamate | 1 |
77 | forcibly | 8 |
78 | from.50 | 1 |
79 | fxr/fxr-agonist | 1 |
80 | gastronomically | 1 |
81 | gestationally | 4 |
82 | hemicidrin | 1 |
83 | hepatically | 12 |
84 | heterozygots | 1 |
85 | hplc-purified | 1 |
86 | hypocritically | 1 |
87 | improves/slightly | 1 |
88 | indications/settings | 2 |
89 | inotropically | 1 |
90 | interval/patient | 5 |
91 | involved.patients | 1 |
92 | iridodials | 1 |
93 | isocapnia | 3 |
94 | isoenergetically | 3 |
95 | lack-of-fit | 4 |
96 | lioplast | 1 |
97 | lps-applications | 1 |
98 | lrp2 | 1 |
99 | mabtrem-1 | 1 |
100 | marginal-if | 1 |
101 | meta-chloro | 1 |
102 | metal-on-highly | 3 |
103 | microfat | 3 |
104 | mono-phosphinoyl/thiophosphinoyl | 1 |
105 | monophenoxy | 1 |
106 | n-ethyl-2-pyrrolidinone | 2 |
107 | n-oxide-fleroxacin | 1 |
108 | nanotio2 | 1 |
109 | neutrally | 14 |
110 | non-axisymmetric | 1 |
111 | non-clathrin | 1 |
112 | non-ige | 4 |
113 | non-immunologically | 1 |
114 | non-nhi | 1 |
115 | non-sod | 1 |
116 | nonmasking | 1 |
117 | nonprofessionally | 1 |
118 | ns8593 | 3 |
119 | p-fluorobenzyl | 1 |
120 | p-tscl | 3 |
121 | pap1 | 1 |
122 | parasympathetically | 2 |
123 | partially | 3,524 |
124 | partialy | 2 |
125 | partly | 1,989 |
126 | partly-be | 1 |
127 | partly/fully | 1 |
128 | performance-bias | 1 |
129 | phosphanyl | 4 |
130 | phospho-signaling | 2 |
131 | polyclonally | 2 |
132 | pre-blood | 4 |
133 | pre-hospital-initiated | 1 |
134 | prefrontally | 2 |
135 | prohibitted | 1 |
136 | prosthodontically | 1 |
137 | provocatively | 3 |
138 | puerperally | 1 |
139 | pyridazin-3-ones | 1 |
140 | rauisuchian | 1 |
141 | reboots | 1 |
142 | reprised | 1 |
143 | rgkitla | 1 |
144 | ru-alkylidene | 1 |
145 | sacm1l | 1 |
146 | segmentally | 11 |
147 | selene | 2 |
148 | self-trapping | 1 |
149 | serotonergically | 5 |
150 | serum/glucocorticoid | 1 |
151 | situation-based | 1 |
152 | sq29548 | 1 |
153 | stattic | 2 |
154 | steroidsulfatase | 3 |
155 | sub-aquatic | 1 |
156 | subconsciously | 5 |
157 | sufonyl | 1 |
158 | sugar/sugar | 1 |
159 | sympathetically | 26 |
160 | t-roundness | 2 |
161 | tandem-dimer | 1 |
162 | tat-59 | 1 |
163 | temporarily | 345 |
164 | thermo-optically | 1 |
165 | thiazolidin-4-ones | 2 |
166 | tidally | 5 |
167 | tim-/- | 1 |
168 | tim-3-expression | 2 |
169 | tobramycin-impregnated | 1 |
170 | toxicopathological-associated | 1 |
171 | trp67 | 1 |
172 | type-could | 1 |
173 | unfeasibility | 2 |
174 | v-1606 | 1 |
175 | vagally | 10 |
176 | val158-were | 1 |
177 | valence-dependently | 1 |
178 | venostasis | 1 |
179 | virologically | 109 |
180 | wall-power | 1 |
181 | wbc-derived | 2 |
182 | well-tolerated.for | 1 |
183 | wilfordine | 1 |
184 | work/daycare | 2 |
185 | ±1.5-fold | 1 |
186 | ß-1,6-gal3 | 1 |
187 | α-nf | 1 |
188 | β-dialkyl | 1 |
189 | β1,6 | 1 |
190 | β2-β3 | 1 |
1 | b6.ahr+/+ | 1 |
2 | tim-/- | 1 |
3 | aaph- | 1 |
4 | 3-methoxy- | 1 |
5 | from.50 | 1 |
6 | 782,850 | 1 |
7 | mabtrem-1 | 1 |
8 | 46,81 | 1 |
9 | cyp21a1 | 2 |
10 | pap1 | 1 |
11 | 58802 | 2 |
12 | cyp1b2 | 1 |
13 | nanotio2 | 1 |
14 | lrp2 | 1 |
15 | 3.8±0.3 | 1 |
16 | 109513 | 1 |
17 | 3,063 | 2 |
18 | ns8593 | 3 |
19 | anti-egfr-igg3 | 5 |
20 | ß-1,6-gal3 | 1 |
21 | β2-β3 | 1 |
22 | are5 | 2 |
23 | β1,6 | 1 |
24 | v-1606 | 1 |
25 | 14,226 | 1 |
26 | 329.467 | 1 |
27 | trp67 | 1 |
28 | sq29548 | 1 |
29 | -c19 | 1 |
30 | tat-59 | 1 |
31 | cys269 | 1 |
32 | anti-mir-302a | 2 |
33 | isocapnia | 3 |
34 | rgkitla | 1 |
35 | -olefinic | 1 |
36 | non-axisymmetric | 1 |
37 | sub-aquatic | 1 |
38 | stattic | 2 |
39 | 0.5-1.5°c | 1 |
40 | dad-induced | 2 |
41 | hplc-purified | 1 |
42 | situation-based | 1 |
43 | reprised | 1 |
44 | toxicopathological-associated | 1 |
45 | pre-hospital-initiated | 1 |
46 | tobramycin-impregnated | 1 |
47 | debrominated | 1 |
48 | prohibitted | 1 |
49 | wbc-derived | 2 |
50 | serum/glucocorticoid | 1 |
51 | ±1.5-fold | 1 |
52 | type-could | 1 |
53 | pre-blood | 4 |
54 | non-sod | 1 |
55 | bacteriaceae | 1 |
56 | partly-be | 1 |
57 | binaphthoxide | 1 |
58 | 1-methyl-5-nitroimidazole-2-aldehyde | 1 |
59 | non-ige | 4 |
60 | described-the | 1 |
61 | aspirin/dipyridamole | 1 |
62 | amphetaime | 1 |
63 | dicubane | 1 |
64 | ru-alkylidene | 1 |
65 | 3-arylidene | 1 |
66 | 7-phosphadibenzonorbornadiene | 1 |
67 | selene | 2 |
68 | wilfordine | 1 |
69 | -sparteine | 1 |
70 | 6β-cinnamoylmorphinamine | 1 |
71 | charge-to-alanine | 1 |
72 | 3',5'-adenosine | 1 |
73 | n-ethyl-2-pyrrolidinone | 2 |
74 | work/daycare | 2 |
75 | val158-were | 1 |
76 | bcc-ti-phase | 1 |
77 | steroidsulfatase | 3 |
78 | flufenamate | 1 |
79 | marginal-if | 1 |
80 | α-nf | 1 |
81 | -asset-building | 1 |
82 | nonmasking | 1 |
83 | phospho-signaling | 2 |
84 | extracellular-signaling | 1 |
85 | self-trapping | 1 |
86 | non-nhi | 1 |
87 | determined.ashmi | 1 |
88 | sacm1l | 1 |
89 | extracellular-signal | 2 |
90 | p-tscl | 3 |
91 | β-dialkyl | 1 |
92 | phosphanyl | 4 |
93 | 6-phenyl | 1 |
94 | sufonyl | 1 |
95 | mono-phosphinoyl/thiophosphinoyl | 1 |
96 | 2-amino-5-arylazo-6-aryl | 2 |
97 | p-fluorobenzyl | 1 |
98 | rauisuchian | 1 |
99 | n-oxide-fleroxacin | 1 |
100 | hemicidrin | 1 |
101 | non-clathrin | 1 |
102 | drift-criterion | 1 |
103 | tim-3-expression | 2 |
104 | disclosure/discrimination | 1 |
105 | c-met-activation | 1 |
106 | cationization | 1 |
107 | meta-chloro | 1 |
108 | 6569dalys/year | 1 |
109 | sugar/sugar | 1 |
110 | tandem-dimer | 1 |
111 | wall-power | 1 |
112 | well-tolerated.for | 1 |
113 | performance-bias | 1 |
114 | 4-hydroxycarbazoles | 1 |
115 | 3-aminodiarylisoxazoles | 1 |
116 | pyridazin-3-ones | 1 |
117 | thiazolidin-4-ones | 2 |
118 | -acetophenones | 1 |
119 | alkyl-3-oxobutanoates | 1 |
120 | compounds/metabolites | 1 |
121 | indications/settings | 2 |
122 | venostasis | 1 |
123 | iridodials | 1 |
124 | concems | 1 |
125 | lps-applications | 1 |
126 | t-roundness | 2 |
127 | involved.patients | 1 |
128 | heterozygots | 1 |
129 | reboots | 1 |
130 | microfat | 3 |
131 | lack-of-fit | 4 |
132 | interval/patient | 5 |
133 | aps-treatment | 2 |
134 | lioplast | 1 |
135 | fxr/fxr-agonist | 1 |
136 | alu-alu | 2 |
137 | duration-may | 1 |
138 | partialy | 2 |
139 | forcibly | 8 |
140 | provocatively | 3 |
141 | ceramic-on-highly | 1 |
142 | metal-on-highly | 3 |
143 | temporarily | 345 |
144 | 'pathophysiologically | 1 |
145 | non-immunologically | 1 |
146 | virologically | 109 |
147 | adrenergically | 1 |
148 | beta2-adrenergically | 1 |
149 | cholinergically | 5 |
150 | serotonergically | 5 |
151 | gastronomically | 1 |
152 | autonomically | 7 |
153 | conically | 2 |
154 | inotropically | 1 |
155 | 2,2-unsymmetrically | 1 |
156 | hepatically | 12 |
157 | isoenergetically | 3 |
158 | sympathetically | 26 |
159 | parasympathetically | 2 |
160 | hypocritically | 1 |
161 | prosthodontically | 1 |
162 | thermo-optically | 1 |
163 | 'focally | 1 |
164 | tidally | 5 |
165 | vagally | 10 |
166 | partially | 3,524 |
167 | nonprofessionally | 1 |
168 | gestationally | 4 |
169 | polyclonally | 2 |
170 | puerperally | 1 |
171 | cognitive-behaviorally | 2 |
172 | neutrally | 14 |
173 | segmentally | 11 |
174 | prefrontally | 2 |
175 | artifactually | 4 |
176 | partly/fully | 1 |
177 | collicularly | 1 |
178 | subconsciously | 5 |
179 | improves/slightly | 1 |
180 | valence-dependently | 1 |
181 | faintly | 10 |
182 | partly | 1,989 |
183 | baroreflexly | 1 |
184 | arctherapy | 1 |
185 | 35dry | 3 |
186 | craniocentricity | 1 |
187 | activity/seasonality | 1 |
188 | unfeasibility | 2 |
189 | monophenoxy | 1 |
190 | 10‰ | 1 |